SURVEYS

• HealthActCHQ has overseen the translation of each of the 130 versions of the CHQ into more than 60 languages.VIEW OUR TRANSLATIONS
• HealthActCHQ is the exclusive licensor of AIM-A, an industry-leading ADHD survey for adults (AIM-A), now available in 12 languages, as well as AIM-C, the only published ADHD quality of life survey available for children and their families.
• All HealthActCHQ quality of life surveys are used throughout Africa, Australia, Asia, Europe, North America, and South America in clinical trials, clinical practice, school systems, clinical care networks, patient-based registries and population-based quality of life outcomes research.
• Our surveys meet or exceed 2006 FDA guidelines on patient-reported outcomes and apply to the following U.S. and European Union legislative directives:
  
• U.S. FDA Center for Drug Evaluation and Research, Best Pharmaceuticals for Children Act, 4 January, 2002 (Public Law No. 107-109)
• U.S. FDA Center for Drug Evaluation and Research, Pediatric Research Equity Act of 2003 (Public Law No. 108-155)
• The Paediatric Regulation (Regulation (EC) No 1901/2006) of the European Parliament, 26 January 2007
• Our patient-based surveys are rigorously developed to include feedback from children and adults varying in subtype, severity, treatment status and time of onset/diagnosis. Our patient-based surveys also combine feedback from clinical experts, comprehensive psychometric testing, and interpretation and analysis based on 20 years in the applied health outcomes field. (Use of any HealthActCHQ survey requires registration and licensure for each project, as well as payment of the licensing fees.) LEARN MORE ABOUT OUR SURVEYS
• Our surveys have a long lineage, including publication in peer-reviewed scientific journals. VIEW OUR BIBLIOGRAPHY